Результаты поиска

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0-27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; Pversus 63.2

Совпадение в полном тексте источника
… and Europe for MM patients who have received ≥1 prior therapy. 15 , 16 In addition, daratumumab plus pomalidomide and dexamethasone was approved in the United States for MM patients after 2 prior therapies including lenalidomide and a PI. 15 More recently, daratumumab in combination with bortezomib, melphalan …

Multifunctional Actions of Ninjinyoeito, a Japanese Kampo Medicine: Accumulated Scientific Evidence Based on Experiments With Cells and Animal Models, and Clinical Studies.

Herbal medicines are currently employed for the treatment of several types of diseases, and also employed for the improvement of Quality of Life (QOL) of patients over the world, in particular, in Asian countries. In Japan, a Japanese herbal medicine namely kampo medicine has been prescribed for the improvement of QOL of patients. Ninjinyoeito (NYT), composed of 12 herbal plants, is one of kampo medicines and used for helping recovery of diseases and improving several symptoms that suffer patients such as anemia, anorexia and fatigue. Recent scientific research approaches to kampo medicines wi

Совпадение в полном тексте источника
… For these patients over 65 years, Melphalan-prednisone (MP) therapy has been employed ( 5 ). In this study, MP treatment lowered the concentrations of several cytokines such as RANTES, sE-selectin, but not Ang-2 and VEGF. …

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.

Treatment options for patients with multiple myeloma (MM) have increased during the past decade. Despite the significant advances, challenges remain on which combination strategies will provide the optimal response for any given patient. Defining optimal combination strategies and corresponding companion diagnostics, that will guide clinical decisions are required to target relapsed or refractory multiple myeloma (RRMM) in order to improve disease progression, survival and quality of life for patients with MM. Elotuzumab is a humanized monoclonal antibody that targets signaling lymphocytic act

Совпадение в полном тексте источника
… Patients had previously received one to three lines of therapy involving bortezomib (70%), ASCT (55%), melphalan (65%), thalidomide (48%) and lenalidomide (6%). 38 Patients received 28-day cycles of lenalidomide 25 mg orally (days 1–21) and dexamethasone 40 mg weekly with or without elotuzumab 10 mg …

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Multiple myeloma (MM) is a plasma cell disorder preceded by monoclonal gammopathy of undetermined significance (MGUS). Incidence of MM and MGUS is higher among patients with autoimmune disease. The aim of this study was to determine whether a history of autoimmunity has an impact on survival in MM and MGUS. Using high-quality national Swedish registries, we identified 8367 patients with MM, 18,768 patients with MGUS, and 110,251 matched control subjects, and obtained information on previous autoimmune disease in patients and controls. Cox regression was used to calculate hazard ratios (HRs) fo

Совпадение в полном тексте источника
… Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013;27:695–701. doi: 10.1038/leu.2012.271. 40. …

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among pa

Совпадение в полном тексте источника
… This is different from what is reported for other therapies for MM such as high-dose melphalan and lenalidomide. 25 Both are dependent on renal function for clearance, and dose modification is recommended based on severity of renal impairment to minimize hematologic toxicity. …

Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma.

BACKGROUND: We previously reported that changes of 6-17 percent in the EORTC QLQ-C30 scores are regarded important by patients with multiple myeloma and thus may be considered as Minimal Important Differences (MIDs). However, patients' internal standard of measurement may have changed over time (response shift, RS). In the present work, we evaluated whether myeloma patients experience RS and if this could affect the MID-estimates. METHODS: Between 2006 and 2008, 239 patients with multiple myeloma completed the EORTC QLQ-C30 at baseline (T1) and after three months (T2). At T2, patients were as

Совпадение в полном тексте источника
… Table 1 Patient characteristics MP: Melphalan and Prednisone ASCT: Autologous stem cell transplantation | Multiple myeloma patients N = 239 Age (year) | Median (range) | 66 (36-89) Sex, no. (%) | Male | 128 (54) Female | 111 (46) Phase of disease, no. (%) | Newly diagnosed | 87 (36) Stable disease …

Clinical review: specific aspects of acute renal failure in cancer patients.

Acute renal failure (ARF) in cancer patients is a dreadful complication that causes substantial morbidity and mortality. Moreover, ARF may preclude optimal cancer treatment by requiring a decrease in chemotherapy dosage or by contraindicating potentially curative treatment. The pathways leading to ARF in cancer patients are common to the development of ARF in other conditions. However, ARF may also develop due to etiologies arising from cancer treatment, such as nephrotoxic chemotherapy agents or the disease itself, including post-renal obstruction, compression or infiltration, and metabolic o

Совпадение в полном тексте источника
… Patient characteristics | Age | Pre-existing liver disease | Hormonal treatment Conditioning regimen | Cyclophosphamide | Total body irradiation | Busulfan | Carmustine | Carboplatin | Thiotepa | Melphalan | Gemtuzumab ozogamicin Transplant source | HLA-identical non-related donor | HLA mismatch …

Long-Term Results of Hematopoietic Cell Transplantation (HCT) for Adults with Blood Disorders- A Systematic Review.

Both autologous and allogeneic stem cell transplantations are widely used as a standard of care or significant clinical option in treating various malignant and non-malignant diseases of the hematopoietic system. The value of these treatment methods would be better assessed through the review of long-term progression-free and overall survival (PFS and OS) rates, which are highly dependent on the primary diagnosis and stage of disease at the time of transplantation as well as on the specific type of used transplantation procedure. While the best (over 90%) 5-, 10- and 15-year survival rates are

Совпадение в полном тексте источника
… Long-term follow-up of multiple myeloma patients treated with tandem autologous transplantation following melphalan and upon recovery, total marrow irradiation. Transplantation and Cellular Therapy, 28 (7), 367.e1-367.e9. 10.1016/j.jtct.2022.04.022 11. … High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: Single-center results. Transplantation Proceedings, 46 (8), 2877–2881. 10.1016/j.transproceed.2014.09.053 12. Vesole, D. H., Pérez, W. S., Akasheh, M., Boudreau, C., Reece, D. E., Bredeson, C. …

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal dysfunction, infection, bone pain, hypercalcemia, and fatigue. Despite numerous recent advancements in the MM treatment paradigm, current therapies demonstrate limited long-term effectiveness and eventual disease relapse remains exceedingly common. Myeloma cells often develop drug resistance through clonal evolution and alterations of cellular signaling pathways. Therefore, con

Совпадение в полном тексте источника
… In this study, CIML NK cells were infused 24 h after 200 mg/m 2 melphalan administration, and interim data show a 3-fold expansion with a peak on day +28 and persistence until day +60. No severe AEs were noted other than anticipated infusion reactions [ 120 ]. 9.2. … Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): A multicentre, randomised, open-label, phase 3 study …

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies.

Multiple myeloma is a hematological cancer type. For its treatment, Bortezomib has been widely used. However, drug resistance to this effective chemotherapeutic has been developed for various reasons. 2D cell cultures and animal models have failed to understand the MM disease and Bortezomib resistance. It is therefore essential to utilize new technologies to reveal a complete molecular profile of the disease. In this review, we in-depth examined the possible molecular mechanisms that cause Bortezomib resistance and specifically addressed MM and Bortezomib resistance. Moreover, we also included

Совпадение в полном тексте источника
… In MM, the expression of LRP was observed in patients treated with Melphalan [ 71 ] and Bortezomib [ 29 ]. The MRP family responsible for MDR includes nine members (MRP-1, MRP-2, MRP-3, MRP-4, MRP-5, MRP-6, MRP-7, MRP-8, MRP-9). … cell | - | Investigation of MM cells osteogenesis, angiogenesis, tumor growth, and drug response | [ 135 ] 2D/3D coculture | Withaferin A | Cytotoxicity | [ 136 ] 2D/Hydrogel based 3D ex vivo co-culture system | Pomalidomide Lenalidomide Thalidomide Bortezomib Carfilzomib Doxorubicin Dexamethasone Melphalan …

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.

Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinical

Совпадение в полном тексте источника
… Recruiting NCT04519476 2 Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Active, not recruiting NCT02186834 3 Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Recruiting NCT02780609 4 A Study … 1 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | Recruiting | NCT04519476 2 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | Active, not recruiting | NCT02186834 3 | Selinexor Plus High-Dose Melphalan …

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at relatively low levels in other tissues, making it a suitable target for therapeutic antibodies. Several anti-CD38 therapies have been, or are being, developed for the treatment of MM, including daratumumab and isatuximab (SAR650984), respectively. Studies have shown that anti-CD38 therapies are effective in the treatment of relapsed/refractory MM and

Совпадение в полном тексте источника
… Moreover, two large phase 3, randomized, first-line trials evaluating the addition of daratumumab to standard induction therapies including daratumumab combined with: (i) lenalidomide and dexamethasone (MAIA; ClinicalTrials.gov, NCT02252172 ), and (ii) bortezomib, melphalan and prednisone (ALCYONE; ClinicalTrials.gov … Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma N. Engl. J. Med. 2018 378 518 528 10.1056/NEJMoa1714678 29231133 91. Moreau P. Attal M. Hulin C. Arnulf B. Belhadj K. Benboubker L. Bene M.C. Broijl A. Caillon H. Caillot D. …

Plasma Cell Disorders

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… In the feline literature, many individual reports describe the usage of a wide range of options from no therapy to the use of steroids alone, or more commonly, combination chemotherapy protocols including melphalan and prednisolone (the most commonly used combination); COP (cyclophosphamide, vincristine … However, caution must be employed in the usage of melphalan in cats. A typical historical regime has been the administration of a 2 mg tablet every four days (equating to approximately 8 mg/m 2 for a 4 kg [9 lb] cat). …

Integrative Hematology: State of the Art.

Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was conceived as a discipline that enriches the patient's therapeutic possibilities with the use of supplements, vitamins and a nutritional approach aiming at improving the response to therapies and the clinical outcome. We will analyze the substances that have proved most useful in preclinical and clinical s

Совпадение в полном тексте источника
… In in vitro and murine models, it increases chemosensitivity to dexamethasone, doxorubicin and melphalan, and synergizes with the action of bortezomib and thalidomide [ 88 ]. … Sulforaphane: This isothiacyanate deriving from Cruciferae has been shown to have an action similar to Bortezomib in inhibiting the degradation of IkB (the Nkb inhibitor), and, finally, shows synergy with dexamethasone, doxorubicin, bortezomib and melphalan. …

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.

PurposeOur preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity. We conducted an investigator-initiated clinical trial to evaluate PELA in combination with dexamethasone (Dex) and bortezomib (BZ) and define the tumor immune microenvironment (TiME) in patients with multiple myeloma treated with this regimen.Patients and methodsPatients with relapsed/refractory multiple myeloma (n = 14) were enrolled in a phase Ib clinical trial (ClinicalTrials.gov: NCT02514382) of three escalating PELA doses administered on D

Совпадение в полном тексте источника
… (5, PD) Len maintenance (N/A, N/A), CyPom (N/A, N/A), Doxil (N/A, N/A), Carfil/Dex (18, PD), Dara (2, PD), Benda/Len/Dex (N/A, PR), CyPom (N/A, N/A) | BZ, Carfil/Dex, Dara | 1 | 45 | PD | 1 | PD | 28 | Lost to follow-up | 1 | FC; Cytokine; TCR-seq; IHC 14 | M | 1q+, t(11;14), complex vt(11;14) | BZ/Melphalan … Auto Tx, Len maintenance (N/A, 18, N/A), Carfil/Dex (8, Relapse), Dara/Pom/Dex (N/A, PD) | BZ/ Melphalan, Carfil, Dara/Pom | 1 | 74 | PD | 2 | SD | 43 | Died | 19 | FC; Cytokine; TCR-seq; IHC; IMC Safety and toxicity Cohort 1 (3×10 10 TCID 50 PELA) included 5 patients, Cohort 2 (4.5×10 10 TCID 50 PELA …

Boosting Immunity against Multiple Myeloma.

Despite the improvement of patient's outcome obtained by the current use of immunomodulatory drugs, proteasome inhibitors or anti-CD38 monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. More recently, the testing in clinical trials of novel drugs such as anti-BCMA CAR-T cells, antibody-drug conjugates or bispecific antibodies broadened the possibility of improving patients' survival. However, thus far, these treatment strategies have not been able to steadily eliminate all malignant cells, and the aim has been to induce a long-term complete response with minimal residua

Совпадение в полном тексте источника
… The use of high doses of melphalan has been shown to induce immunogenic cell death, increase of inflammatory cytokines production, enhance tumor antigen uptake by dendritic cells (DCs) with subsequent antigen presentation to lymphocytes [ 17 ]. … Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J. Immunol. 2015;194:2011–2021. doi: 10.4049/jimmunol.1401894. 18. …

The Application of CAR-T Cells in Haematological Malignancies.

Chimeric antigen receptor (CAR)-T cells (CART) remain one of the most advanced and promising forms of adoptive T-cell immunotherapy. CART represent autologous, genetically engineered T lymphocytes expressing CAR, i.e. fusion proteins that combine components and features of T cells as well as antibodies providing their more effective and direct anti-tumour effect. The technology of CART construction is highly advanced in vitro and every element of their structure influence their mechanism of action in vivo. Patients with haematological malignancies are faced with the possibility of disease rela

Совпадение в полном тексте источника
… One of them was a phase I clinical trial ( NCT02135406 ) that focused on the safety, tolerability and engraftment potential of modified CD19-targeting CART in patients with MM after the melphalan treatment and autologous stem cell transplantation. … Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018;3:e120505. doi: 10.1172/jci.insight.120505. Geyer MB, Rivière I, Sénéchal B, et al. …

Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis.

BACKGROUND: Chemoradiotherapy-associated mucositis can manifest as pain, inflammation, dysphagia, diarrhea, weight loss, rectal bleeding, and infection. Mucositis is a major dose-limiting side effect of chemotherapy, affecting nutritional intake and oral and intestinal function. Despite several interventions being available, there is a need for safe and effective preventative and treatment options for treatment-induced mucositis. The goals of this review are to discuss interventions based on foods and natural products and present the research to date. METHODS: A narrative literature review id

Совпадение в полном тексте источника
… day versus placebo | Sar/NB | RCT crossover study (pediatric n = 24), patient questionnaire | Decreased OM duration/severity ( P < .05) Okuno et al 48 | 5-FU | Glutamine 30 g oral/day versus placebo | Not defined | RCT (n = 134), assessed by physician | NS benefit Cockerham et al 49 | Paclitaxel and melphalan … Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother. 2000;34:300-303. 50. Dickson TMC, Wong RM, Offrin RS, et al. …

Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review.

Despite rapid advances in treatment approaches of multiple myeloma (MM) over the last two decades via proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs), their efficacies are limited. MM still remains incurable, and the majority of patients shortly relapse and eventually become refractory to existing therapies due to the genetic heterogeneity and clonal evolution. Therefore, the development of novel therapeutic strategies with different mechanisms of action represents an unmet need to achieve a deep and highly durable response as well as to improve pa

Abstracts for the Eighth Congress of the European Association for Neuro-Oncology (EANO) : September 12–14, 2008 Barcelona, Spain

Background: Standard treatment consisting of surgery, irradiation plus concomitant and following T is established in GBM with median surviva … ce of disease progression, five sequential courses of chemotherapy followed by ASCT were performed: melphalan (100 mg/m2) at day 43, cisplatin (100 mg/m2) at day 64, melphalan at day 85, cisplatin at day 106 and thiotepa (720 mg/m2) at day 127. Children with resectable tumor residue were operated at the end of chemotherapy. Treatment was completed by age-ad …